ClinicalTrials.Veeva

Menu

Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

AstraZeneca logo

AstraZeneca

Status and phase

Suspended
Phase 2

Conditions

Carcinoma, Renal Cell
Kidney Neoplasms

Treatments

Drug: ZD6126
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00065572
D2820C00018
6126IL/00018

Details and patient eligibility

About

The purpose of this study is to assess the biological activity of ZD6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage IV).

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Newly diagnosed metastatic renal cell carcinoma
  • Suitable for nephrectomy

Exclusion criteria

  • Prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma or within the last 3 years for any other cancer
  • Significant cardiac event within 3 months of entry
  • Any history of coronary angioplasty or history of myocardial infarction

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

16

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems